Season 2 - Ep.21: Drug treatment of HCM - Humour in medicine

5 snips

Aug 1, 2024

Guest

Milind Desai

Join leading cardiology experts Carlos Aguiar and Milind Desai, alongside the witty Rohin Francis, as they delve into the latest advancements in drug treatments for hypertrophic cardiomyopathy. They discuss innovative therapies, including cardiac myosin inhibitors, and evaluate their efficacy and safety. The trio also highlights the healing power of humor in medicine, sharing how laughter can enhance patient communication and reduce anxiety. Plus, dive into the fundamentals of regression analysis in medical research for a comprehensive and entertaining experience!

Ask episode

Chapters

Transcript

Episode notes

Intro

00:00 • 3min

Long-term Risks in High Bleeding Risk Patients Post-PCI and New Guidelines on Pulmonary Hypertension

03:15 • 3min

Advancements in HCM Drug Treatments

06:36 • 7min

The Healing Power of Humor in Medicine

13:17 • 7min

Understanding Regression Analysis in Medical Research

20:29 • 6min

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies
Drug treatment of hypertrophic cardiomyopathy
Humour in medicine
Statistics Made Easy: Regression analysis

Host: Susanna Price

Guests: Carlos Aguiar, Milind Desai, Rohin Francis

Want to watch that episode? Go to: https://esc365.escardio.org/event/1156

Disclaimer:

ESC TV Today and ESC 365, the cardiology knowledge hub are supported by Bristol Myers Squibb.

The scientific content and opinions expressed in this programme have not been influenced in any way by its sponsor.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Rohin Francis, Antonio Greco, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic.

Milind Desai has declared to have potential conflicts of interest to report: consultant and research agreements with Bristol Myers Squibb, Tenaya, Edgewise, Cytokinetics and VIZ AI.

Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.